France seeks Russian vaccines, Sputnik V will sue Brazil

France seeks Russian vaccines, Sputnik V will sue Brazil

On April 29, Russian President Vladimir Putin held an online meeting with French businesses, calling on them to help Russia in changing the attitudes of European leaders on Russian vaccines, such as Sputnik V. .

Vaccine search Russia, Sputnik V will be in Brazil
President Putin in the online meeting of French companies.

General Director of the French-Russian Chamber of Commerce and Industry Pavel Shinsky, who participated in the presidential meeting with the French business community, said the French pharmaceutical company Sanogi participated in the online meeting.

Mr. Pavel Shinsky said: “I believe it is not a secret that the president calls on Russian-French investors to also influence the existing European regulatory mechanisms and services so that they can ensure their security. Russian development and goods have the same loyal attitude to the French in particular and foreigners in general to receive in Russia. “

Clearly, necessary activities discussed between Russia and France are “procurement, localization, and even vaccine production”.

“The president has reasonably said about this goal, saying that there must be assurance that these vaccines will be tested in Europe. It makes no sense to invest funds in production if an item may not get the license to use it, “he added.

Sputnik V sued Brazil for spreading false rumors

Russian developer of the COVID-10 vaccine, Sputnik V, recently announced his intention to sue Anvisa, the Brazilian Health Administration, for deliberately spreading inaccurate information.

“After the Brazilian regulator Anvisa admitted that it was not testing the Sputnik V vaccine, Sputnik V is conducting a legal proceeding in Brazil against Anvisa for intentionally spreading false and inaccurate information.” – The announcement from vaccine developer Sputnik V states.

Earlier, Gustavo Mendes, Anvisa’s bio-product and drug manager, said that the regulator did not receive the Sputnik V vaccine sample for testing and did not perform the relevant testing as a procedure. required to license vaccines in this country.

Anvisa earlier this week rejected Russia’s application for a license for the Sputnik V vaccine. The meeting was announced to last for more than 4 hours, then informed by Anvisa that the conclusions from the consulting agencies and experts showed that the effectiveness and safety of the vaccine were not appropriate.

Earlier, France24 newspaper France24 reported that the batch of Russian vaccine COVID-19, Sputnik V, was alleged to contain a poisoned virus. Russian vaccine batches sent to Brazil contain “a live version of a virus that causes the common cold”.

Lead virologist Angela Rasmussen said that the finding “raises questions about the integrity of manufacturing processes” and could be a safety issue for people with weaker immune systems, if Detected problems are common.

The Russian Institute of Gamaleya, which developed the Sputnik V vaccine, has denied these reports. They claim it is an “adenovirus vector” – a virus that normally causes mild respiratory illness, but in the vaccine it is genetically engineered so that it cannot replicate and is modified to carry DNA instructions to human cells to transmit. Show mutated proteins of the corona virus. Thus, they “train” the human system to prepare them in case of a real corona virus.

Sputnik V uses two different adenovirus vectors to do this: adenovirus type 26 (Ad26) for the first shot and adenovirus type 5 (Ad5) for the second injection.

But scientists at Anvisa, Brazil’s regulator, say they have examined samples of the booster shot and found it “replicable” – that is, once inside the body, adenovirus. can continue to multiply.

They added that this could be caused by a manufacturing problem called “recombination”, in which the modified adenovirus regained the genes needed for regeneration while it was being developed laterally. in human cells. Obviously, if in people with compromised immune systems, they can cause a higher incidence of side effects, including serious ones.

She said that this is a pity that even a famous scientific journal like The Lancet still gives the vaccine a high rating with an efficiency of more than 90%.

Hai Lam


Related Posts